ArticleFrontiers in pharmacology2026
Luteolin mitigates proliferative vitreoretinopathy through inhibition of ERK1/2 signaling and epithelial-mesenchymal transition.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural Product-Based Nanomedicine in the Treatment of Breast Cancer.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To investigate the inhibitory effect of luteolin on proliferative vitreoretinopathy (PVR) and explore its potential mechanism. Methods: Human retinal pigment epithelial ARPE-19 cells were treated with luteolin (0-50 μM) to assess its effects on cell viability, migration, and TGF-β2-induced epithelial-mesenchymal transition (EMT). Cell viability (CCK-8), Scratch and Transwell assays, flow cytometric cell-cycle analysis, immunofluorescence, and Western blotting were performed to evaluate α-SMA, vimentin, and p-ERK1/2 expression. Results: Our results revealed that luteolin, at concentrations of 12.5 μM and 25μM, significantly inhibited the horizontal and vertical migration ability of ARPE-19 cells. Luteolin, at concentrations of 12.5 μM and 25μM, also effectively inhibited the expression of EMT-related mesenchymal proteins induced by TGF-β2 in ARPE-19 cells. Luteolin inhibited intraocular mesenchymal proteins increase in experimental PVR in mice, followed by downregulation of p-ERK1/2 protein expression. Conclusion: Luteolin suppresses RPE cell migration and EMT both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.